These emerging therapies , Semaglutide , represent a remarkable advancement in treating metabolic dysfunction and conceivably other disorders. These drugs are classified as GLP-1 pathway activators , indicating they function to replicate the endogenous GLP-1 peptide, stimulating metabolic release